The journal of headache and pain · 2017
Patients' preferences for headache acute and preventive treatment.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mitsikostas Dimos D, Belesioti Ioanna, Arvaniti Chryssa, Mitropoulou Euthymia, Deligianni Christina, Kasioti Elina, Constantinidis Theodoros, Dermitzakis Manolis, Vikelis Michail, Hellenic Headache Society
Аннотация
BACKGROUND: We aimed to explore patients' preferences for headache treatments with a self-administered questionnaire including the Q-No questionnaire for nocebo.
METHODS: Questionnaires from 514 outpatients naïve to neurostimulation and monoclonal antibodies were collected.
RESULTS: Patients assessed that the efficacy of a treatment is more important than safety or route of administration. They preferred to use an external neurostimulation device for both acute (67.1%) and preventive treatment (62.8%). Most patients preferred to take a pill (86%) than any other drug given parenterally for symptomatic pharmaceutical treatment. For preventive pharmaceutical treatment, most patients preferred to take a pill once per day (52%) compared to an injection either subcutaneously or intravenously each month (9% and 4%), or three months (15% and 11%). 56.6% of all participants scored more than 15 in Q-No questionnaire indicating potential nocebo behaviors that contributed significantly in their choices.
CONCLUSION: These patient preferences along with efficacy and safety data may help physicians better choose the right treatment for the right person.
METHODS: Questionnaires from 514 outpatients naïve to neurostimulation and monoclonal antibodies were collected.
RESULTS: Patients assessed that the efficacy of a treatment is more important than safety or route of administration. They preferred to use an external neurostimulation device for both acute (67.1%) and preventive treatment (62.8%). Most patients preferred to take a pill (86%) than any other drug given parenterally for symptomatic pharmaceutical treatment. For preventive pharmaceutical treatment, most patients preferred to take a pill once per day (52%) compared to an injection either subcutaneously or intravenously each month (9% and 4%), or three months (15% and 11%). 56.6% of all participants scored more than 15 in Q-No questionnaire indicating potential nocebo behaviors that contributed significantly in their choices.
CONCLUSION: These patient preferences along with efficacy and safety data may help physicians better choose the right treatment for the right person.